Cell Therapy

Cell therapy improved visual acuity in a review of 18 clinical trials involving 224 eyes across AMD, SMD, and RP. Moderate-quality evidence for cell therapy showed a visual acuity improvement with a mean difference of +0.25 (95% CI 0.15 to 0.45) on the logMAR scale. The recommendation for cell therapy remained weak due to moderate statistical heterogeneity, risk of bias, and imprecision. Safety evidence for cell therapy was moderate quality, with low heterogeneity for adverse events suggesting low risk.